STOCK TITAN

R1 RCM Inc. - RCM STOCK NEWS

Welcome to our dedicated page for R1 RCM news (Ticker: RCM), a resource for investors and traders seeking the latest updates and insights on R1 RCM stock.

R1 RCM Inc. (NASDAQ: RCM) is a distinguished leader in the field of revenue cycle management, serving hospitals, health systems, and physician groups throughout the United States. Leveraging cutting-edge technology, R1 RCM Inc. provides comprehensive solutions designed to enhance the financial performance and patient experience for healthcare providers.

Founded with a mission to streamline healthcare operations, R1 RCM's suite of services includes end-to-end revenue cycle management, technology-driven solutions, and process workflows aimed at improving operating margins, cash flows, and overall satisfaction among patients, physicians, and staff. The company’s technology solutions seamlessly integrate with healthcare providers' existing infrastructure, resulting in sustainable improvements in net patient revenue and operational efficiency.

In recent developments, R1 RCM Inc. reported preliminary financial results for the fourth quarter of 2023, anticipating revenues between $563 to $567 million, marking a 6 to 6.5 percent increase compared to the previous year. This growth is primarily driven by double-digit increases in modular revenue, despite some delays in new client transitions and lower incentive fees. The company also anticipates an operating income of $36 to $39 million and a net loss of $8 to $10 million, with an adjusted EBITDA ranging from $163 to $166 million.

R1 recently completed the acquisition of Acclara from Providence, one of the nation’s largest health systems, establishing a 10-year partnership that is expected to significantly enhance the company’s revenue cycle services. This acquisition is projected to contribute over $625 million in revenue and approximately $185 million to adjusted EBITDA within five years.

R1 RCM's commitment to innovation is evident in its recent advancements through generative AI, and its environmental, social, and governance (ESG) efforts, which align with the United Nations Sustainable Development Goals. The company's 2023 ESG report showcases numerous achievements, underlining its dedication to responsible global citizenship and sustainable business practices.

For further information and updates, visit the company’s official website at r1rcm.com.

Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences
-
News
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) has entered into a definitive agreement to acquire Acclara, a leading technology-driven revenue cycle management company, from Providence, and has been selected by Providence as its long-term revenue cycle management partner. The partnership lays the foundation for R1 to continue to automate revenue management and to extend its scale and diversification to build long-term value for providers, patients, and shareholders. The proposed acquisition of Acclara and 10-year Providence partnership demonstrate the strength and flexibility of the R1 business model, and R1’s ability to deploy advanced technology solutions and drive execution across revenue cycle management processes to improve customer and patient outcomes. R1 expects the transaction to provide a foundation for additional growth opportunities by expanding the end-to-end relationship with Providence and other Acclara customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) has completed the restatement of its financial statements for 2022 and 2021, with no material impact on revenue or Adjusted EBITDA. The restatement had no impact on the company's cash, business operations, or 2023 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
none
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) received a letter from Nasdaq’s Listing Qualifications Department due to a delay in filing its Quarterly Report. The delay was caused by the Company's determination to restate certain previously issued financial statements. The notice requires the Company to submit a plan to regain compliance within 60 days, with a possible extension of up to 180 days. The Company intends to file the Form 10-Q as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) Restates Financial Statements for 2022 and 2021, No Material Impact on 2023 Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) to present at 2023 Stephens Annual Investment Conference and 6th Annual Evercore ISI HealthCONx Conference, offering live webcasts and replays on r1rcm.com
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences
Rhea-AI Summary
R1 RCM Inc. has announced an expansion of its collaboration with Microsoft to integrate generative AI into its healthcare revenue cycle management platform. The company has launched its first large language model (LLM) application that improves physician coding quality. The application uses Microsoft Azure AI services to evaluate medical records and predict physician evaluation and management codes, improving coding quality across patient charts. R1 plans to leverage LLMs on applications across the revenue cycle to achieve greater automation and improve patient satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.25%
Tags
none
-
Rhea-AI Summary
R1 RCM Inc. (NASDAQ: RCM) announced its third quarter 2023 results, reporting a revenue of $572.8 million, a 15.5% increase compared to the same period last year. The company also achieved a GAAP net income of $1.3 million, compared to a net loss of $29.5 million in the same period last year. Adjusted EBITDA reached $161.5 million, a 30.2% increase compared to the same period last year. R1 expects to generate a revenue of $2,255 million to $2,275 million for 2023. The company's management team will host a conference call to discuss the financial results and business outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.25%
Tags
-
Rhea-AI Summary
R1 RCM Inc. to release financial results for Q3 2023 on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
Rhea-AI Summary
James Hardie Industries plc has announced the appointment of Rachel Wilson as Chief Financial Officer. Wilson brings over 25 years of experience in the technology, business services, and consumer products industries. She will report directly to CEO Aaron Erter. Wilson's appointment follows the departure of Jason Miele, who will remain with the company for three months as an advisor to the CEO for special projects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none

FAQ

What is the current stock price of R1 RCM (RCM)?

The current stock price of R1 RCM (RCM) is $14.31 as of November 19, 2024.

What is the market cap of R1 RCM (RCM)?

The market cap of R1 RCM (RCM) is approximately 6.0B.

What does R1 RCM Inc. do?

R1 RCM Inc. provides technology-driven revenue cycle management services to hospitals, health systems, and physician groups in the United States, enhancing financial performance and the patient experience.

What recent achievements has R1 RCM Inc. made?

R1 RCM Inc. reported a 6 to 6.5 percent increase in preliminary fourth-quarter 2023 revenues and completed the acquisition of Acclara to further enhance its service offerings.

What is the significance of the Acclara acquisition?

The acquisition of Acclara from Providence establishes a 10-year partnership expected to contribute over $625 million in revenue and approximately $185 million to adjusted EBITDA within five years.

How does R1 RCM Inc. enhance the patient experience?

R1 RCM Inc. uses scalable, technology-driven solutions that integrate with healthcare providers' infrastructure to streamline operations, improve cash flows, and enhance overall patient satisfaction.

What are the financial highlights for R1 RCM Inc. for the fourth quarter of 2023?

R1 RCM Inc. anticipates fourth-quarter revenues between $563 to $567 million, an operating income of $36 to $39 million, and adjusted EBITDA between $163 to $166 million.

How does R1 RCM Inc. contribute to sustainability?

R1 RCM Inc. is committed to sustainability and responsible global citizenship, as highlighted in its 2023 ESG report, which aligns with the United Nations Sustainable Development Goals.

Where can I find more information about R1 RCM Inc.?

You can find more information and the latest updates about R1 RCM Inc. on their official website at r1rcm.com.

What is R1 RCM Inc.'s primary source of revenue?

The majority of R1 RCM Inc.'s revenue comes from operating fees received for their comprehensive revenue cycle management services provided to health systems, hospitals, and physician groups.

What technologies does R1 RCM Inc. utilize?

R1 RCM Inc. employs advanced technology solutions, including generative AI, to enhance operational efficiency and drive sustainable improvements in healthcare revenue cycles.

What is the mission of R1 RCM Inc.?

The mission of R1 RCM Inc. is to make healthcare work better for all by transforming the financial performance and patient experience for healthcare providers through innovative technology-driven solutions.
R1 RCM Inc.

Nasdaq:RCM

RCM Rankings

RCM Stock Data

6.04B
198.59M
1.04%
86.91%
2.56%
Health Information Services
Services-management Services
Link
United States of America
MURRAY